Literature DB >> 2668430

Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins.

E L Lopez1, M Diaz, S Grinstein, S Devoto, F Mendilaharzu, B E Murray, S Ashkenazi, E Rubeglio, M Woloj, M Vasquez.   

Abstract

Shiga-like toxin-producing Escherichia coli have been associated with hemorrhagic colitis and the hemolytic uremic syndrome (HUS). Because Argentina has the highest reported frequency of HUS in the world, Argentine children were prospectively studied during the HUS seasons for evidence of Shiga-like toxin-related diseases. On the basis of serology, fecal cytotoxin neutralization, stool cultures, and DNA hybridization of colony lysates, most children with HUS had evidence of infection with Shiga-like toxin-producing organisms. Children with spring-summer diarrhea also commonly (32%, confidence interval 18%-46%) had clear-cut evidence of such infection. No controls (children without gastrointestinal, renal, or hemolytic disease) had free fecal cytotoxin, positive cultures for E. coli O157:H7, or DNA probe-positive organisms; 20% of them had low serum titers of antibodies to Shiga-like toxins. E. coli O157:H7 was not common in either HUS or diarrhea patients. The high frequency of Shiga-like toxin-induced diarrhea in young children in Argentina probably explains the high incidence of HUS in this country and suggests that HUS is a relatively uncommon complication of Shiga-like toxin-related disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668430     DOI: 10.1093/infdis/160.3.469

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Impaired detection of faecal verocytotoxin in the presence of Clostridium difficile cytotoxin in patients with haemolytic uraemic syndrome.

Authors:  I Luzzi; F Minelli; A Gianviti; A Caprioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

3.  Prevalence and virulence factors of Escherichia coli serogroups O26, O103, O111, and O145 shed by cattle in Scotland.

Authors:  M C Pearce; J Evans; I J McKendrick; A W Smith; H I Knight; D J Mellor; M E J Woolhouse; G J Gunn; J C Low
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

4.  Terminology of hemolytic-uremic syndrome.

Authors:  R N Srivastava
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 5.  Genetic basis of virulence in Shigella species.

Authors:  T L Hale
Journal:  Microbiol Rev       Date:  1991-06

6.  Impact of free verotoxin testing on epidemiology of diarrhea caused by verotoxin-producing Escherichia coli.

Authors:  K Ramotar; E Henderson; R Szumski; T J Louie
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Adherence of enterohemorrhagic Escherichia coli strains to a human colonic epithelial cell line (T84).

Authors:  D K Winsor; S Ashkenazi; R Chiovetti; T G Cleary
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.

Authors:  S W Lindgren; J E Samuel; C K Schmitt; A D O'Brien
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003.

Authors:  Alexandra Schifferli; Rodo O von Vigier; Matteo Fontana; Giuseppina Spartà; Hans Schmid; Mario G Bianchetti; Christoph Rudin
Journal:  Eur J Pediatr       Date:  2009-10-15       Impact factor: 3.183

10.  Virulence factors and phenotypical traits of verotoxigenic strains of Escherichia coli isolated from human patients in Germany.

Authors:  L Beutin; S Aleksic; S Zimmermann; K Gleier
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.